compound PARP / PI 3 K inhibition Vulnerabilities of PTEN-p 53-deficient prostate cancers to

[1]  P. Pandolfi,et al.  Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.

[2]  P. Pandolfi,et al.  The functions and regulation of the PTEN tumour suppressor , 2012, Nature Reviews Molecular Cell Biology.

[3]  Emma E Vincent,et al.  Akt signalling in health and disease. , 2011, Cellular signalling.

[4]  Jung-Sik Kim,et al.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.

[5]  C. Schnell,et al.  Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. , 2008, Cancer research.

[6]  C. Benes,et al.  Class 1A PI3K regulates vessel integrity during development and tumorigenesis , 2008, Proceedings of the National Academy of Sciences.

[7]  E. Metter,et al.  Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. , 2007, The Journal of urology.

[8]  O. Nalcioglu,et al.  In vivo MRI volumetric measurement of prostate regression and growth in mice , 2007, BMC urology.

[9]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[10]  Theodore L DeWeese,et al.  Clinical practice. Localized prostate cancer. , 2007, The New England journal of medicine.

[11]  F. Gallyas,et al.  Pivotal Role of Akt Activation in Mitochondrial Protection and Cell Survival by Poly(ADP-ribose)polymerase-1 Inhibition in Oxidative Stress* , 2005, Journal of Biological Chemistry.

[12]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[13]  T. Pandita,et al.  Lack of PTEN sequesters CHK1 and initiates genetic instability. , 2005, Cancer cell.

[14]  P. Pandolfi,et al.  Pten Dose Dictates Cancer Progression in the Prostate , 2003, PLoS biology.

[15]  C. Sawyers,et al.  The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Carlos Cordon-Cardo,et al.  Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.

[17]  J Downward,et al.  PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. , 1997, Trends in biochemical sciences.

[18]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[19]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.